Abstract

BackgroundCanine chronic bronchitis (CCB) results in cough lasting ≥2 months and airway inflammation. Adverse effects include risk of secondary infection associated with lifelong corticosteroid administration and prompt investigation into alternative therapies. Neurogenic pathways mediated by tachykinins that bind neurokinin (NK) 1 receptors may induce cough and airway inflammation. Maropitant,1 a NK‐1 receptor antagonist, has been advocated for treatment of CCB based on anecdotal improvement, but without scientific evidence.Hypothesis/ObjectivesMaropitant1 will blunt clinical signs and airway inflammation associated with CCB.AnimalsClient‐owned dogs (n = 8) with cough >2 months, thoracic radiographic evidence of airway disease and sterile airway inflammation (>7% non‐degenerate neutrophils, >7% eosinophils or both) on bronchoalveolar lavage (BAL) enrolled.MethodsMaropitant1 (2 mg/kg) administered q48h for 14 days. Study endpoints included client perception of clinical signs (surveys at baseline and 14 days, and visual analogue scale [VAS] at baseline, 7, and 14 days), and BAL % neutrophils and eosinophils (baseline and 14 days). One‐way repeated measures ANOVA (VAS) and Wilcoxon‐signed rank‐sum tests (BAL cells, cough frequency) used with P < .05 considered significant.ResultsMaropitant1 significantly decreased cough frequency (P < .001) and VAS scores (P = .005). No differences in BAL % neutrophils or % eosinophils noted with treatment (P = .279 and P = .382, respectively).Conclusions and Clinical ImportancePreliminary results suggest that although maropitant1 may have antitussive properties leading to perceived clinical improvement, its failure to diminish airway inflammation makes it unsuitable for treatment of CCB. Future studies could evaluate maropitant1 as a cough suppressant for other respiratory disorders in dogs.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.